Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2005 1
2006 1
2007 5
2008 3
2009 2
2010 4
2011 7
2012 3
2013 3
2014 4
2015 5
2016 3
2017 1
2018 1
2019 4
2020 5
2021 18
2022 21
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Among authors: yang z. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, Wiese RJ, Tuttle KR, Cherney DZI. Heerspink HJL, et al. Among authors: yang z. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785. doi: 10.1016/S2213-8587(22)00243-1. Epub 2022 Sep 21. Lancet Diabetes Endocrinol. 2022. PMID: 36152639 Clinical Trial.
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. Tolaney SM, et al. Among authors: yang z. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. doi: 10.1158/1078-0432.CCR-20-1764. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694159 Clinical Trial.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Among authors: yang z. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.
Cancer and Ongoing Climate Change: Who Are the Most Affected?
Yu P, Xu R, Yang Z, Ye T, Liu Y, Li S, Abramson MJ, Kimlin M, Guo Y. Yu P, et al. Among authors: yang z. ACS Environ Au. 2022 Aug 31;3(1):5-11. doi: 10.1021/acsenvironau.2c00012. eCollection 2023 Jan 18. ACS Environ Au. 2022. PMID: 36691655 Free PMC article. Review.
Global climate change and human health: Pathways and possible solutions.
Zhao Q, Yu P, Mahendran R, Huang W, Gao Y, Yang Z, Ye T, Wen B, Wu Y, Li S, Guo Y. Zhao Q, et al. Among authors: yang z. Eco Environ Health. 2022 May 7;1(2):53-62. doi: 10.1016/j.eehl.2022.04.004. eCollection 2022 Jun. Eco Environ Health. 2022. PMID: 38075529 Free PMC article. Review.
108 results